Diplomat Pharmacy (NYSE:DPLO) had its price objective raised by Morgan Stanley from $16.00 to $21.00 in a report published on Tuesday morning. Morgan Stanley currently has an equal weight rating on the stock.
Several other research firms also recently weighed in on DPLO. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a hold rating to a sell rating in a report on Tuesday, May 1st. Barclays initiated coverage on shares of Diplomat Pharmacy in a report on Thursday, March 8th. They issued an overweight rating and a $27.00 target price for the company. JPMorgan Chase & Co. upgraded shares of Diplomat Pharmacy from a neutral rating to an overweight rating in a report on Thursday, May 10th. Leerink Swann reiterated an outperform rating and issued a $33.00 target price on shares of Diplomat Pharmacy in a report on Friday, June 22nd. Finally, ValuEngine upgraded shares of Diplomat Pharmacy from a hold rating to a buy rating in a report on Saturday, June 16th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $26.64.
Shares of Diplomat Pharmacy opened at $26.15 on Tuesday, according to MarketBeat.com. The company has a market cap of $1.91 billion, a PE ratio of 31.13 and a beta of 1.33. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.88 and a quick ratio of 0.57. Diplomat Pharmacy has a 1 year low of $14.23 and a 1 year high of $28.74.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, May 7th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.01). The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The firm’s quarterly revenue was up 24.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 EPS. sell-side analysts expect that Diplomat Pharmacy will post 0.92 EPS for the current fiscal year.
In other Diplomat Pharmacy news, Director Shawn Tomasello sold 1,680 shares of the firm’s stock in a transaction that occurred on Tuesday, June 5th. The shares were sold at an average price of $24.27, for a total value of $40,773.60. Following the completion of the transaction, the director now owns 12,816 shares of the company’s stock, valued at approximately $311,044.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey G. Park sold 13,875 shares of the firm’s stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $24.20, for a total transaction of $335,775.00. The disclosure for this sale can be found here. Insiders sold a total of 17,250 shares of company stock valued at $419,364 in the last three months. 24.70% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. USA Financial Portformulas Corp purchased a new position in Diplomat Pharmacy in the 4th quarter valued at approximately $544,000. Arrowstreet Capital Limited Partnership purchased a new position in Diplomat Pharmacy in the 4th quarter valued at approximately $423,000. Arizona State Retirement System boosted its position in Diplomat Pharmacy by 226.7% in the 4th quarter. Arizona State Retirement System now owns 81,033 shares of the company’s stock valued at $1,626,000 after buying an additional 56,233 shares during the period. Teacher Retirement System of Texas purchased a new position in Diplomat Pharmacy in the 4th quarter valued at approximately $328,000. Finally, Fred Alger Management Inc. boosted its position in Diplomat Pharmacy by 1.2% in the 4th quarter. Fred Alger Management Inc. now owns 610,405 shares of the company’s stock valued at $12,251,000 after buying an additional 7,193 shares during the period. 75.66% of the stock is owned by institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.